ATYR ▼ -9.3% - aTyr Pharma, Inc. $ATYR - aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis aTyr Pharma shares fell 9.3% following the company's announcement of a timing update on its regulatory response related to a planned Phase 3 study of efzofitimod in pulmonary sarcoidosis. The stock decline likely reflects investor concern about delays or unfavorable feedback in the regulatory review process for this key pipeline program. 01-SEP-2026 04:36 PM ET